New pill takes on KRAS-Mutant cancers in early trial

NCT ID NCT06447662

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 4 times

Summary

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will give the drug alone or combined with other cancer treatments to find the safest dose and see if it helps control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-07934040 (a pan-KRAS inhibitor pill)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced cancers driven by KRAS mutations, including lung, colorectal, and pancreatic cancers.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet proven to work. Side effects are unknown, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal carcinoma colorectal neoplasm lung neoplasm neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, PANCREATIC DUCTAL COLORECTAL NEOPLASMS

Contacts and locations

Locations

Barnes-Jewish Hospital

St Louis, Missouri, 63110, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, 91010, United States
City of Hope Investigational Drug Service (IDS)

Duarte, California, 91010, United States
Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Duke University Medical Center, lnvestigational Chemotherapy Service

Durham, North Carolina, 27710, United States
Highlands Oncology Group

Springdale, Arkansas, 72762, United States
Highlands Oncology Group, PA

Fayetteville, Arkansas, 72703, United States
Highlands Oncology Group, PA

Rogers, Arkansas, 72758, United States
Miriam Hospital

Providence, Rhode Island, 02906, United States
Pan American Center for Oncology Trials, LLC

Rio Piedras, 00935, Puerto Rico
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Siteman Cancer Center

St Louis, Missouri, 63108, United States
Siteman Cancer Center - North County

Florissant, Missouri, 63031, United States
Siteman Cancer Center - South County

St Louis, Missouri, 63129, United States
Siteman Cancer Center - St Peters

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center - West County

Creve Coeur, Missouri, 63141, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion

Aurora, Colorado, 80045, United States
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)

Aurora, Colorado, 80045, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
West Chester Hospital

West Chester, Ohio, 45069, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.